A Nonsense Mutation in the ERG6 Gene Leads to Reduced Susceptibility to Polyenes in a Clinical Isolate of Candida glabrata

ABSTRACT Unlike the molecular mechanisms that lead to azole drug resistance, the molecular mechanisms that lead to polyene resistance are poorly documented, especially in pathogenic yeasts. We investigated the molecular mechanisms responsible for the reduced susceptibility to polyenes of a clinical isolate of Candida glabrata. Sterol content was analyzed by gas-phase chromatography, and we determined the sequences and levels of expression of several genes involved in ergosterol biosynthesis. We also investigated the effects of the mutation harbored by this isolate on the morphology and ultrastructure of the cell, cell viability, and vitality and susceptibility to cell wall-perturbing agents. The isolate had a lower ergosterol content in its membranes than the wild type, and the lower ergosterol content was found to be associated with a nonsense mutation in the ERG6 gene and induction of the ergosterol biosynthesis pathway. Modifications of the cell wall were also seen, accompanied by increased susceptibility to cell wall-perturbing agents. Finally, this mutation, which resulted in a marked fitness cost, was associated with a higher rate of cell mortality. Wild-type properties were restored by complementation of the isolate with a centromeric plasmid containing a wild-type copy of the ERG6 gene. In conclusion, we have identified the molecular event responsible for decreased susceptibility to polyenes in a clinical isolate of C. glabrata. The nonsense mutation detected in the ERG6 gene of this isolate led to a decrease in ergosterol content. This isolate may constitute a useful tool for analysis of the relevance of protein trafficking in the phenomena of azole resistance and pseudohyphal growth.

[1]  M. Bard,et al.  Genome-wide expression profiling reveals genes associated with amphotericin B and fluconazole resistance in experimentally induced antifungal resistant isolates of Candida albicans. , 2004, The Journal of antimicrobial chemotherapy.

[2]  D. Ellis Amphotericin B: spectrum and resistance. , 2002, The Journal of antimicrobial chemotherapy.

[3]  P. Benveniste,et al.  Two families of sterol methyltransferases are involved in the first and the second methylation steps of plant sterol biosynthesis. , 1998, European journal of biochemistry.

[4]  D. Sanglard,et al.  Candida albicans Mutations in the Ergosterol Biosynthetic Pathway and Resistance to Several Antifungal Agents , 2003, Antimicrobial Agents and Chemotherapy.

[5]  M. Richardson,et al.  Changing patterns and trends in systemic fungal infections. , 2005, The Journal of antimicrobial chemotherapy.

[6]  C. Hennequin,et al.  Reduced Susceptibility to Polyenes Associated with a Missense Mutation in the ERG6 Gene in a Clinical Isolate of Candida glabrata with Pseudohyphal Growth , 2006, Antimicrobial Agents and Chemotherapy.

[7]  Stephen H. Bryant,et al.  CD-Search: protein domain annotations on the fly , 2004, Nucleic Acids Res..

[8]  C. Clancy,et al.  A Candida albicans Petite Mutant Strain with Uncoupled Oxidative Phosphorylation Overexpresses MDR1 and Has Diminished Susceptibility to Fluconazole and Voriconazole , 2007, Antimicrobial Agents and Chemotherapy.

[9]  R. Prasad,et al.  Multidrug Transporters CaCdr1p and CaMdr1p of Candida albicans Display Different Lipid Specificities: both Ergosterol and Sphingolipids Are Essential for Targeting of CaCdr1p to Membrane Rafts , 2007, Antimicrobial Agents and Chemotherapy.

[10]  P. Poupard,et al.  Mechanisms of Azole Resistance in Petite Mutants of Candida glabrata , 2004, Antimicrobial Agents and Chemotherapy.

[11]  F. Odds,et al.  Candida and Torulopsis: a blinded evaluation of use of pseudohypha formation as basis for identification of medically important yeasts , 1997, Journal of clinical microbiology.

[12]  Akihiko Nakano,et al.  Ergosterol is required for targeting of tryptophan permease to the yeast plasma membrane , 2003, The Journal of cell biology.

[13]  Wenxu Zhou,et al.  Probing the sterol binding site of soybean sterol methyltransferase by site-directed mutagenesis: functional analysis of conserved aromatic amino acids in Region 1. , 2006, Archives of biochemistry and biophysics.

[14]  W. D. Nes,et al.  Enzyme mechanisms for sterol C-methylations. , 2003, Phytochemistry.

[15]  M. Bard,et al.  Sequencing, Disruption, and Characterization of the Candida albicans Sterol Methyltransferase (ERG6) Gene: Drug Susceptibility Studies in erg6 Mutants , 1998, Antimicrobial Agents and Chemotherapy.

[16]  J. Wingard,et al.  Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia , 1997, Antimicrobial agents and chemotherapy.

[17]  J. Sobel,et al.  Candida glabrata: Review of Epidemiology, Pathogenesis, and Clinical Disease with Comparison toC. albicans , 1999, Clinical Microbiology Reviews.

[18]  John R Perfect,et al.  Resistance to Antifungal Agents: Mechanisms and Clinical Impact , 2008 .

[19]  J. Bouchara,et al.  Mechanisms of Azole Resistance in a Clinical Isolate of Candida tropicalis , 2005, Antimicrobial Agents and Chemotherapy.

[20]  Narmada Thanki,et al.  CDD: a conserved domain database for interactive domain family analysis , 2006, Nucleic Acids Res..

[21]  M. Zupancic,et al.  A yeast by any other name: Candida glabrata and its interaction with the host. , 2005, Current opinion in microbiology.

[22]  D. Kelly,et al.  Resistance to fluconazole and cross‐resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol Δ5,6‐desaturation , 1997, FEBS letters.

[23]  S. Kelly,et al.  Isolation and analysis of ketoconazole resistant mutants of Saccharomyces cerevisiae. , 1988, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

[24]  J. Bouchara,et al.  In-vitro resistance to azoles associated with mitochondrial DNA deficiency in Candida glabrata. , 1999, Journal of medical microbiology.

[25]  F. Karst,et al.  Regulation of early enzymes of ergosterol biosynthesis in Saccharomyces cerevisiae. , 1986, The Biochemical journal.

[26]  J. Oxford Specific inhibitors of influenza virus replication as potential chemoprophylactic agents. , 1975, The Journal of antimicrobial chemotherapy.

[27]  D. Sanglard,et al.  Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. , 2002, The Lancet. Infectious diseases.

[28]  K. Kavanagh,et al.  Disruption of mitochondrial function in Candida albicans leads to reduced cellular ergosterol levels and elevated growth in the presence of amphotericin B , 2003, Archives of Microbiology.

[29]  J. Bujnicki,et al.  Sterol methyltransferase: functional analysis of highly conserved residues by site-directed mutagenesis. , 2004, Biochemistry.

[30]  R. Filmon,et al.  In-vivo selection of an azole-resistant petite mutant of Candida glabrata. , 2000, Journal of medical microbiology.

[31]  Serguei Sokol,et al.  Investigating the caffeine effects in the yeast Saccharomyces cerevisiae brings new insights into the connection between TOR, PKC and Ras/cAMP signalling pathways , 2006, Molecular microbiology.

[32]  Y. Uehara,et al.  Regulated overexpression of CDR1 in Candida albicans confers multidrug resistance. , 2004, The Journal of antimicrobial chemotherapy.

[33]  M. Bard,et al.  Cloning of the late genes in the ergosterol biosynthetic pathway ofSaccharomyces cerevisiae—A review , 1995, Lipids.